| Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax (NCT05092373) | M.D. Anderson Cancer Center | 2022-04-29 |
| A Video Intervention to Improve Patient Understanding of Tumor Genomic Testing in Patients With Metastatic Cancer (NCT05215769) | Ohio State University Comprehensive Cancer Center | 2022-03-30 |
| Evaluation of Barriers to Cancer Care Delivery and Outcomes for Women of Color With Metastatic Breast Cancer (NCT06206239) | Thomas Jefferson University | 2022-03-09 |
| Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer (NCT04673448) | University of Washington | 2021-10-18 |
| Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial (NCT04704661) | National Cancer Institute (NCI) | 2021-08-09 |
| Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Maintenance Treatment (Trastuzumab and Pertuzumab) After Initial Chemotherapy in a Phase Ib/II Trial for Advanced HER2 Positive Breast Cancer (NCT04108858) | National Cancer Institute (NCI) | 2021-05-20 |
| Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations (NCT04550494) | National Cancer Institute (NCI) | 2021-04-26 |
| Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer (NCT04498520) | Pamela Munster | 2021-03-31 |
| Immunotherapy (NHS-IL12 & Bintrafusp Alfa) and Radiation Therapy for the Treatment of Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer, the REINA Trial (NCT04756505) | M.D. Anderson Cancer Center | 2021-03-07 |
| 18F-FMAU PET/CT and MRI for the Detection of Brain Tumors in Patients With Brain Cancer or Brain Metastases (NCT04752267) | University of Southern California | 2021-02-15 |
| Apollo Device for Metastatic Breast Cancer (MBC) (NCT04983342) | Margaret Quinn Rosenzweig | 2021-02-01 |
| Breast Cancer Vaccine in Combination With Pembrolizumab for Treatment of Persistent, Recurrent, or Metastatic Breast Cancer (NCT04418219) | Thomas Jefferson University | 2020-12-21 |
| Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors (NCT04541225) | Nuvation Bio Inc. | 2020-12-08 |
| Optimizing Treatment of Stage IV Breast Cancer Through Real-Time Disease Monitoring (NCT04906369) | Mayo Clinic | 2020-11-16 |
| T-DM1 With or Without Abemaciclib for the Treatment of HER2-Positive Metastatic Breast Cancer (NCT04351230) | Academic and Community Cancer Research United | 2020-11-11 |
| Using FDG-PET/CT to Assess Response of Bone-Dominant Metastatic Breast Cancer, FEATURE Study (NCT04316117) | ECOG-ACRIN Cancer Research Group | 2020-09-15 |
| Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer (NCT04090567) | M.D. Anderson Cancer Center | 2020-07-28 |
| Biomarkers and Clinical Features of Metastatic Breast Cancer in Patients Treated With CDK4/6 Inhibitors (NCT04526587) | Roswell Park Cancer Institute | 2020-07-03 |
| Testing the Addition of Copanlisib to Usual Treatment (Fulvestrant and Abemaciclib) in Metastatic Breast Cancer (NCT03939897) | National Cancer Institute (NCI) | 2020-06-17 |
| Stereotactic Radiosurgery With Abemaciclib, Ribociclib, or Palbociclib in Treating Patients With Hormone Receptor Positive Breast Cancer With Brain Metastases (NCT04585724) | Emory University | 2020-06-12 |
| Feasibility of Integrating the Outcomes4Me Smartphone Navigation Application Into the Care Management of Breast Cancer Patients (NCT04262518) | Outcomes4Me | 2020-06-01 |
| Alpha-TEA and Trastuzumab for the Treatment of Refractory HER2+ Metastatic Breast Cancer (NCT04120246) | Veana Therapeutics | 2020-04-08 |
| Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial (NCT03878524) | OHSU Knight Cancer Institute | 2020-04-01 |
| Abemaciclib and Endocrine Therapy in Older Patients With Breast Cancer. (NCT04305834) | City of Hope Medical Center | 2020-03-25 |
| Paclitaxel Therapeutic Drug Monitoring in Cancer Patients (NCT03987555) | Wake Forest University Health Sciences | 2019-11-11 |
| Clinical Information and Biospecimen Collection From Patients With Recurrent or Stage IV Breast Cancer (NCT03737695) | Mayo Clinic | 2019-09-16 |
| Alpelisib and Enzalutamide in Treating Patients With Androgen Receptor and PTEN Positive Metastatic Breast Cancer (NCT03207529) | M.D. Anderson Cancer Center | 2019-06-07 |
| Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT Study (NCT04256941) | M.D. Anderson Cancer Center | 2019-05-31 |
| Intravital Microscopy in Human Solid Tumors (NCT03823144) | Mayo Clinic | 2019-02-28 |
| A Study of a New Drug Combination, Copanlisib and Fulvestrant, in Advanced Breast Cancer (NCT03803761) | National Cancer Institute (NCI) | 2019-02-13 |
| Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone Metastasis (NCT03691493) | Emory University | 2019-02-08 |
| Breast Cancer Pathways Program Impact on Patient Shared Decision Making and Experience in Academic and Community Practice (NCT04297384) | Roswell Park Cancer Institute | 2019-02-06 |
| PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery (NCT03218826) | National Cancer Institute (NCI) | 2018-09-24 |
| Radiation Therapy and M7824 in Treating Patients With Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer (NCT03524170) | M.D. Anderson Cancer Center | 2018-04-30 |
| Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer (NCT03432741) | Mayo Clinic | 2018-03-27 |
| Metastatic Breast Carcinoma and Women Sexual Quality of Life (NCT03408769) | Institut de Cancérologie de Lorraine | 2018-03-12 |
| Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer (NCT03101748) | M.D. Anderson Cancer Center | 2018-02-19 |
| Testing Olaparib Either Alone or in Combination With Atezolizumab in BRCA Mutant Non-HER2-positive Breast Cancer (NCT02849496) | National Cancer Institute (NCI) | 2017-03-30 |
| The p53 Breast Cancer Trial (NCT02965950) | Haukeland University Hospital | 2016-10-01 |
| Pembrolizumab, Endocrine Therapy, and Palbociclib in Treating Postmenopausal Patients With Newly Diagnosed Metastatic Stage IV Estrogen Receptor Positive Breast Cancer (NCT02778685) | City of Hope Medical Center | 2016-09-30 |
| Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases (NCT02595905) | National Cancer Institute (NCI) | 2016-09-15 |
| Onalespib and Paclitaxel in Treating Patients With Advanced Triple Negative Breast Cancer (NCT02474173) | National Cancer Institute (NCI) | 2016-01-15 |
| Testing Whether Treating Breast Cancer Metastases With Surgery or High-Dose Radiation Improves Survival (NCT02364557) | NRG Oncology | 2014-12-24 |
| Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic (NCT02115282) | National Cancer Institute (NCI) | 2014-03-29 |
| Nab-Paclitaxel in Treating Older Patients With Locally Advanced or Metastatic Breast Cancer (NCT01463072) | City of Hope Medical Center | 2012-06-19 |
| Cyclophosphamide and Veliparib in Treating Patients With Locally Advanced or Metastatic Breast Cancer (NCT01351909) | National Cancer Institute (NCI) | 2011-05-02 |
| Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer (NCT01174121) | National Cancer Institute (NCI) | 2010-08-26 |
| Veliparib With or Without Carboplatin in Treating Patients With Stage III or IV Breast Cancer (NCT01149083) | National Cancer Institute (NCI) | 2010-06-30 |
| Fulvestrant With or Without Bortezomib in Patients With Inoperable Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer (NCT01142401) | National Cancer Institute (NCI) | 2010-05-26 |
| Purged Circulating Tumor Cells (CTCs) From Metastatic Breast Cancer (NCT00429182) | M.D. Anderson Cancer Center | 2007-06-01 |